Monday, March 19, 2018 5:55:25 PM
There's two sides to every story.
I agree it's underhanded that a supplier won't sell their product to someone for the purpose you describe.
I also think it's silly that if Glatopia causes someone to develop some future side effect to (generic) copaxone that Teva has to bear the liability. In other words Teva is responsible for the Label, no matter who uses it.
If we really think about it, generics should be put out to the pasture with a simple agreement with the original company that after XX time they are obligated to sell the product for XX dollars. No one can make Copaxone cheaper or better than Teva and it's a waste of money and time to follow our current process.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM